Abstract: Compounds of formula (II): ##STR1## or a pharmaceutically acceptable salt thereof, in which X is an oxygen atom or a bond, R.sup.1 is a hydrogen, fluorine, chlorine or bromine atom or a trifluoromethyl or C.sub.1-4 alkyl group, each of R.sup.2 and R.sup.3 is a hydrogen atom or a C.sub.1-4 alkyl group, R.sup.4 is a C.sub.1-4 alkyl group, R.sup.5 is a hydrogen atom or a C.sub.1-4 alkyl group, and n is an integer of from 1 to 3; are useful as anti-obesity and/or anti-hyperglycaemic agents.

Abstract: Compounds of formula (I), ##STR1## or an N-oxide or pharmaceutically acceptable salt thereof, wherein R.sub.1 is hydrogen, C.sub.1-7 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-7 cycloalkenyl or C.sub.1-4 alkyl substituted by C.sub.2-7 alkenyl, C.sub.2-7 alkynyl, C.sub.3-7 cycloalkyl, hydroxy, thiol, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, carboxy, C.sub.1-4 alkoxycarbonyl, C.sub.1-4 alkanoyl, amino optionally substituted by one or two C.sub.1-4 alkyl or by C.sub.4-6 polymethylene optionally containing an oxygen or nitrogen atom, aminocarbonyl optionally N-substituted by one or two C.sub.1-4 alkyl, or benzoyl or phenyl either being optionally ring-substituted by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or trifluoromethyl, R.sub.2 and R.sub.3 are the same or different and are hydrogen, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halogen or trifluoromethyl, m is 1 to 3 and n is 1 or 2, the hydrogen atom bonded to the C.sub.a carbon atom being trans to the hydrogen atom bonded to the C.sub.

Abstract: Tetrazolyl derivatives of clavulanic acid are described, having the formula: ##STR1## wherein X is an optionally substituted tetrazolyl group attached via a nitrogen atom. These compounds are useful as antibiotics and .beta.-lactamase inhibitors.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl or together are a group X which is C.sub.3-6 polymethylene optionally interrupted by O, S or NR.sub.6 wherein R.sub.6 is hydrogen or C.sub.1-6 alkyl;R.sub.3 is phenyl, optionally substituted by one or more substituents selected from halogen, CF.sub.3, nitro, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.2-7 alkanoyl, carboxyl, C.sub.1-6 alkoxycarbonyl, cyano, CONR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are selected from hydrogen or C.sub.1-6 alkyl or together are a group X; NR.sub.9 R.sub.10 wherein R.sub.9 and R.sub.10 are selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-7 alkanoyl or C.sub.1-6 alkylsulphonyl or together are a group X; SO.sub.2 NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are selected from hydrogen or C.sub.1-6 alkyl or together are a group X or S(O).sub.m R.sub.13 wherein m is 1 or 2 and R.sub.13 is C.sub.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl;R.sub.2 is hydrogen or C.sub.1-6 alkyl;R.sub.3 is hydroxy, nitro, cyano, C.sub.2-10 acyloxy, NR.sub.6 R.sub.7 wherein R.sub.6 and R.sub.7 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.2-7 alkanoyl or C.sub.1-6 alkylsulphonyl; or COR.sub.8 wherein R.sub.8 is hydroxy, C.sub.1-6 alkoxy or NR.sub.9 R.sub.10 wherein R.sub.9 and R.sub.10 are independently selected from hydrogen or C.sub.1-6 alkyl;R.sub.4 is hydrogen, halogen, CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-4 alkyl or any of the groups listed for R.sub.3 ; andR.sub.5 is hydrogen, C.sub.1-4 alkyl or benzyl optionally substituted in the phenyl ring by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.

Abstract: Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkoxysulphinylamino, C.sub.1-6 alkoxysulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.

Abstract: Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, 1-mercapto C.sub.2-7 alkyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino, or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or --C(C.sub.1-6 alkyl)NOH or --C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.

Abstract: The present invention provides the compounds of the formula (II): ##STR1## and salts and esters thereof wherein R.sub.1 is a hydrogen atom or an alkyl group of 1-4 carbon atoms and R.sub.2 is a hydrogen atom or an alkyl group of 1-4 carbon atoms or is joined to R.sub.1 to form part of a 5-, 6- or 7 membered carbocyclic ring. These compounds are .beta.-lactamase inhibitors able to enhance the effectiveness of pencillins and cephalosporins. Their preparation and compositions containing them are described.

Abstract: Compounds of formula (I): ##STR1## wherein: one of X and Y is CO and the other is NH;R.sub.1 is C.sub.1-6 alkoxy or C.sub.1-6 alkylthio;R.sub.2 is hydrogen, trifluoromethyl, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkylsulphinyl, halogen, nitro or amino, aminocarbonyl or aminosulphonyl optionally N-substituted by one or two groups selected from C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl, phenyl or phenyl C.sub.1-4 alkyl groups any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkoxy or nitro groups, or N-disubstituted by C.sub.2-5 polymethylene;R.sub.3 is amino, aminocarbonyl or aminosulphonyl N-substituted by one or two C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl, phenyl or phenyl C.sub.1-4 alkyl groups any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkoxy or nitro groups, or N-disubstituted by C.sub.

Abstract: A circumference measuring device comprising a flexible tape arranged to form a loop of adjustable size; indicating means comprising a scale and a reference mark movable with respect to one another, one end of the said tape being attached to the indicating means such that the indicating means measures the size of the loop; and zeroing means to preset the reference mark at a predetermined position with respect to the scale.

Abstract: Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or -C(C.sub.1-6 alkyl)NOH or -C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.

Abstract: An oral hygiene composition comprises from 0.01 to 2.0% by weight of the composition of a water soluble ionic fluoride, an ionic abrasive material containing metal cations capable of forming a water insoluble fluoride, and between 0.01% and 9% by weight of the composition of a water soluble ionic agent containing the anionic counter ions of the ionic abrasive together with metal cations capable of forming a water soluble fluoride. The composition is useful in reducing or preventing the inactivation of a water soluble ionic fluoride by an ionic abrasive material.

Abstract: A compound of formula (I) or a salt or ester thereof: ##STR1## Pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or pharmaceutically acceptable ester thereof are also disclosed.

Abstract: A class of 6-alkylidene penem compounds of formula (II) have antibacterial and .beta.-lactamase inhibitory properties: ##STR1## where R.sup.1 and R.sup.2 represent hydrogen or optionally substituted hydrocarbon or heterocyclic, and R.sup.3 represents hydrogen or an organic group.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta. lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: Compounds of formula (I): ##STR1## wherein X is methoxy or ethoxy, Y is amino or C.sub.1-6 alkanoylamino, Z is hydrogen, chloro or bromo and R.sub.1 is methyl, chloro or fluoro, have anti-psychotic activity, and are useful in the treatment of CNS disorders. Intermediates for the above compounds are also disclosed.

Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: the first of R.sub.1 and R.sub.2 is hydrogen, C.sub.1-4 alkyl or phenyl optionally substituted by one or two substituents selected from halogen, CF.sub.3, C.sub.1-4 alkoxy or alkyl and the second is SR.sub.4 wherein R.sub.4 is phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl, or NR.sub.5 R.sub.6 wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, phenyl or phenyl C.sub.1-4 alkyl either of which phenyl moieties may be substituted by one or two substituents selected from halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl, or R.sub.5 and R.sub.6 together form C.sub.4-6 polymethylene; andR.sub.3 is hydrogen, C.sub.1-4 alkyl or benzyl and is attached at nitrogen atom 1 or 2, having anti-inflammatory activity, a process for their preparation and their use as pharmaceuticals.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, N-oxide or solvent adduct thereof: ##STR1## wherein: R.sub.1 is C.sub.1-6 alkoxy, C.sub.1-6 alkylthio or, together with R.sub.5 is C.sub.1-2 alkylene, and one of R.sub.2, R.sub.3 and R.sub.4 is hydrogen and the other two together are C.sub.1-2 alkylenedioxy, or the other two are the same or different and are selected from the class of hydrogen, halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkylsulphinyl hydroxy, nitro or amino, aminocarbonyl or aminosulphonyl optionally N-substituted by one or two C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, phenyl or phen C.sub.1-4 alkyl groups or optionally N-disubstituted by C.sub.4-5 polymethylene, or R.sub.1 and R.sub.2 together are C.sub.1-2 alkylenedioxy, and R.sub.3 and R.sub.4 together are C.sub.1-2 alkylenedioxy or R.sub.3 and R.sub.

Abstract: Compounds A--B--C wherein A is 2 imidazolinyl or N-alkyl derivative thereof, B is oxygen, sulphur, CR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are hydrogen or alkyl, or NR.sup.3 wherein R.sup.3 is hydrogen or alkyl, and C is a 5- or 6- membered carbo- or heterocyclic group having a nitrogen containing substituent and up to two other substituents, are useful in treatment of diarrhoea or scours. Certain compounds A--B--C are novel.

Abstract: Disclosed are compounds of the formulaR.sub.1 --Ar--(CH.sub.2).sub.a --X--(CH.sub.2).sub.b --NH--Hetwherein R.sub.1 is guanidino or substituted guanidino, Ar is furandiyl, thiophendiyl, phenylene, pyridinediyl, pyrimidinediyl, thiazolediyl, thiadiazolediyl or imidazolediyl; a is 0, 1 or 2; b is 2, 3, 4 or 5; and Het is a bicyclic heteroary group, and pharmaceutically acceptable salts, quaternized derivatives, N-oxides and solvates thereof. The compounds are useful for the treatment or prophylaxis of disorders relating to excess gastric acid secretion in mammals.